Rodriguez-Rodriguez S, Pomerantz A, Demichelis-Gomez R, Barrera-Lumbreras G, Barrales-Benitez O, Aguayo-Gonzalez A

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 171-175
Archivo PDF: 116.15 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sörensen J, Velikyan I, Sandberg D, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT. Theranostics. 2016;6:262-71.

2. Madani S-H, Rahmati A, Sadeghi E, et al. Survey of Her2-neu expression and its correlation with histology of gastric carcinoma and gastroesophageal junction adenocarcinoma. Asian Pacific J Cancer Prev. 2015;16:7755-8.

3. Zhu Y, Lu D, Lira ME, et al. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. Exp Mol Pathol. 2015;100:287-93.

4. Kiba T, Morii N, Takahashi H, et al. Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer. Mol Clin Oncol. 2016;4:47-50.

5. Wesoła M, Jelen M. A comparison of IHC and FISH cytogenetic methods in the evaluation of HER2 status in breast cancer. Adv Clin Exp Med. 2015;24:899-904.

6. Zhao Y, Dong X, Li R, Song J, Zhang D. Correlation between clinical-pathologic factors and long-term follow-up in young breast cancer patients. Transl Oncol. 2015;8:265-72.

7. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol. 2011;22:1308-17.

8. Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One. 2011;6:1-9.

9. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/ neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene. 2014;33:429-39.

10. Torres S, Simmons C, Boileau J-F, McLeod D, Martins I, Trudeau M. Patterns in target-directed breast cancer research. Springerplus. 2016;5:1-15.

11. Bühring HJ, Sures I, Jallal B, et al. The receptor tyrosine kinase p185 HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995;85:1916-23.

12. Müller MR, Grünebach F, Kayser K, et al. Expression of Her-2/ neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res. 2003;9:3448-53.

13. Chevallier P, Robillard N, Wuilleme-Toumi S, Méchinaud F, Harousseau JL, Avet-Loiseau H. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica. 2004;89:1399-401.

14. Chevallier P, Robillard N, Houille G, et al. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases. Leukemia. 2009;23:806-7.

15. Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood. 2012;119:2474-7.

16. Haen SP, Schmiedel BJ, Rothfelder K, et al. Prognostic relevance of HER2 / neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. Oncotarget. 2016;7:1-18.

17. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-48.

18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in. J Clin Oncol. 2002;20:719-26.

19. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children’s oncology group pilot study. J Clin Oncol. 2008;26:3756-62.